Aptevo Therapeutics Inc. (APVO)
Stock Price:
$8.09 USD
-0.31 (-3.69%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
26.15M |
| Revenue (ttm) |
32.42M |
| Net Income (ttm) |
-25.53M |
| Shares Out |
3.23M |
| EPS (ttm) |
-7.64 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 3, 2020 |
| Last Price |
$8.09 |
| Previous Close |
$8.40 |
| Change ($) |
-0.31 |
| Change (%) |
-3.69% |
| Day's Open |
8.38 |
| Day's Range |
8.07 - 8.44 |
| Day's Volume |
134,565 |
| 52-Week Range |
2.94 - 14.28 |
More Stats
| Market Cap |
26.15M |
| Enterprise Value |
14.47M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
3.23M |
| Float |
2.41M |
| EPS (basic) |
-7.93 |
| EPS (diluted) |
-7.64 |
| FCF / Share |
-12.15 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
193,600 |
| Short Ratio |
0.03 |
| Short % of Float |
1.61% |
| Beta |
2.76 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
0.81 |
| PB Ratio |
1.83 |
| Revenue |
32.42M |
| Operating Income |
-39.21M |
| Net Income |
-25.53M |
| Free Cash Flow |
-39.71M |
| Net Cash |
11.69M |
| Net Cash / Share |
3.62 |
| Gross Margin |
-53.23% |
| Operating Margin |
-120.94% |
| Profit Margin |
-100.50% |
| FCF Margin |
-122.48% |
| ROA |
-46.02% |
| ROE |
-158.28% |
| ROIC |
-165.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$32.33*
(299.63% upside)
Low
24.0
Current: $8.09
High
42.0
Target: 32.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 32.42 | 23.07 | 14.66 | 9.99 | 33.60 | 45.63 | 0.17 |
| Revenue Growth | 40.56% | 57.37% | 46.8% | -70.28% | -26.36% | 26741.76% | - |
| Gross Profit | 12.50 | 11.85 | 9.65 | -2.48 | 16.67 | 29.38 | 0.17 |
| Operating Income | -42.60 | -51.67 | -53.95 | -139 | -61.10 | -51.71 | -53.34 |
| Net Income | -40.45 | -53.69 | 6.97 | -112 | -59.32 | -51.12 | -53.34 |
| Shares Outstanding | 2.92 | 1.61 | 1.52 | 1.45 | 1.45 | - | - |
| Earnings Per Share | -13.86 | -33.46 | 4.62 | -77.70 | -41.02 | - | - |
| Operating Cash Flow | -42.38 | -51.42 | -41.57 | -36.86 | -48.76 | -47.01 | -51.39 |
| Capital Expenditures | -0.15 | -0.98 | -1.40 | -2.51 | -1.53 | -0.99 | -1.02 |
| Free Cash Flow | -42.54 | -52.40 | -42.98 | -39.37 | -50.29 | -48.00 | -52.41 |
| Cash & Equivalents | 19.95 | 30.64 | 81.18 | 54.93 | 4.64 | 3.59 | 0.00 |
| Total Debt | 23.19 | 19.28 | 19.06 | 18.38 | - | - | - |
| Net Cash / Debt | -3.24 | 11.36 | 62.12 | 36.54 | 4.64 | 3.59 | 0.00 |
| Assets | 53.41 | 67.49 | 117 | 91.86 | 128 | 120 | - |
| Liabilities | 41.57 | 37.09 | 34.97 | 41.29 | 39.15 | 25.36 | - |
| Book Value | 11.84 | 30.41 | 82.04 | 50.57 | 88.62 | 94.61 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aptevo Therapeutics Inc. |
| Country |
United States |
| Employees |
80 |
| CEO |
Marvin L. White |
Stock Information
| Ticker Symbol |
APVO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: APVO |
Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.